{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T03:06:41Z","timestamp":1761102401014},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Small molecule inhibitors, including B-cell receptor antagonists and B-cell lymphoma - 2 inhibitors, have revolutionized the treatment of chronic lymphocytic leukemia (CLL). These agents have improved outcomes for patients of all prognostic backgrounds, thus securing their role in the frontline setting. Impressive activity has been demonstrated both with monotherapy and in combination with other targeted therapeutics. The most important remaining question is whether to administer small molecule inhibitors in a sequential fashion or in combination with each other and\/or anti-CD20\u2013directed therapy. Together, a number of retrospective and prospective clinical trials have provided insight into patient outcomes with different sequencing and combination strategies. While rituximab does not appear to provide significant additional benefit to ibrutinib, the incorporation of venetoclax appears to enable a deeper response and allow for a shorter duration of therapy. How durable of a response this produces and whether patients can be effectively retreated with venetoclax remain unclear. As various targeted therapy doublets and triplets are explored, it is important to investigate whether they produce significant long-term benefits over monotherapy and whether these approaches are appropriate for all patients.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000410","type":"journal-article","created":{"date-parts":[[2019,11,25]],"date-time":"2019-11-25T06:32:50Z","timestamp":1574663570000},"page":"449-454","source":"Crossref","is-referenced-by-count":1,"title":["Targeted Therapies in Chronic Lymphocytic Leukemia"],"prefix":"10.1097","volume":"25","author":[{"given":"Chaitra","family":"Ujjani","sequence":"first","affiliation":[{"name":"Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, WA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce D.","family":"Cheson","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"bib1-20230924","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1093\/annonc\/mdx031","article-title":"Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients","volume":"28","year":"2017","journal-title":"Ann Oncol"},{"key":"bib2-20230924","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial","volume":"19","year":"2018","journal-title":"Lancet Oncol"},{"key":"bib3-20230924","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1182\/blood-2017-06-788133","article-title":"Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy","volume":"131","year":"2018","journal-title":"Blood"},{"key":"bib4-20230924","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1182\/blood-2016-05-716977","article-title":"Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real-world experience","volume":"128","year":"2016","journal-title":"Blood"},{"issue":"S2","key":"bib5-20230924","first-page":"88","article-title":"A phase 2 study to assess the safety and efficacy of umbralisib in patients with chronic lymphocytic leukemia who are intolerant prior BTK or PI3K delta inhibitor therapy","volume":"37","year":"2019","journal-title":"Int Conf Malignant Lymph"},{"key":"bib6-20230924","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1182\/bloodadvances.2018030007","article-title":"Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib","volume":"3","year":"2019 May 14","journal-title":"Blood Adv"},{"key":"bib7-20230924","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","year":"2019","journal-title":"N Engl J Med"},{"key":"bib9-20230924","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","year":"2014","journal-title":"N Engl J Med"},{"key":"bib10-20230924","first-page":"1","article-title":"Efficacy and safety of ibrutinib in relapsed\/refractory chronic lymphocytic leukemia patients previously treated with venetoclax in the Murano Study","volume":"3","year":"2019","journal-title":"HemaSphere"},{"key":"bib11-20230924","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"bib12-20230924","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","year":"2014","journal-title":"N Engl J Med"},{"key":"bib13-20230924","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2018-10-879429","article-title":"Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia","volume":"133","year":"2019","journal-title":"Blood"},{"issue":"suppl","key":"bib14-20230924","article-title":"Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: results of the GENUINE phase 3 study [abstract]","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib15-20230924","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","year":"2018","journal-title":"N Engl J Med"},{"key":"bib16-20230924","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","year":"2019","journal-title":"N Engl J Med"},{"key":"bib17-20230924","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1 suppl","key":"bib18-20230924","article-title":"Acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: updated results from the phase 1\/2 ACE-CL-001 study [abstract]","volume":"130","year":"2017","journal-title":"Blood"},{"key":"bib19-20230924","doi-asserted-by":"crossref","first-page":"7500","DOI":"10.1200\/JCO.2019.37.15_suppl.7500","article-title":"Acalabrutinib with obinutuzumab (Ob) in treatment-naive (TN) and relapsed\/refractory (R\/R) chronic lymphocytic leukemia (CLL): three-year follow-up","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib20-20230924","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","article-title":"Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib21-20230924","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1200\/JCO.18.01580","article-title":"Fixed duration of venetoclax-rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase III study","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"key":"bib22-20230924","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY study","volume":"37","year":"2019","journal-title":"J Clin Oncol"},{"issue":"suppl","key":"bib23-20230924","article-title":"Phase 2 CAPTIVATE results of ibrutinib plus venetoclax in first-line chronic lymphocytic leukemia","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"bib24-20230924","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and venetoclax for first-line treatment of CLL","volume":"380","year":"2019","journal-title":"N Engl J Med"},{"key":"bib25-20230924","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1182\/blood-2018-05-853564","article-title":"Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia","volume":"132","year":"2018","journal-title":"Blood"},{"key":"bib26-20230924","first-page":"431","article-title":"Initial results of the phase 2 treatment naive cohort in a phase 1b\/2 study of obinutuzumab, ibrutinib, and venetoclax in chronic lymphocytic leukemia","volume":"130","year":"2017","journal-title":"Blood"},{"key":"bib27-20230924","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1182\/bloodadvances.2019000180","article-title":"A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R\/R CLL","volume":"3","year":"2019","journal-title":"Blood Adv"},{"key":"bib28-20230924","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1182\/bloodadvances.2018019422","article-title":"Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL","volume":"2","year":"2018","journal-title":"Blood Adv"},{"key":"bib29-20230924","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1182\/blood-2015-12-683516","article-title":"Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL","volume":"127","year":"2016","journal-title":"Blood"},{"key":"bib30-20230924","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1016\/S2352-3026(18)30196-0","article-title":"Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study","volume":"6","year":"2019","journal-title":"Lancet Haematol"},{"key":"bib31-20230924","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2016.67.1305","article-title":"Minimal residual disease assessment improves prediction of outcome in patients with chronic lymphocytic leukemia (CLL) who achieve partial response: comprehensive analysis of two phase III studies of the German CLL Study Group","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib32-20230924","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","article-title":"Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia","volume":"127","year":"2016","journal-title":"Blood"},{"key":"bib33-20230924","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","year":"2018","journal-title":"N Engl J Med"},{"key":"bib34-20230924","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study","volume":"18","year":"2017","journal-title":"Lancet Oncol"},{"key":"bib35-20230924","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1182\/blood-2018-99-110847","article-title":"Up to 7 years of follow-up of single-agent ibrutinib in the phase 1b\/2 PCYC-1102 trial of first line and relapsed\/refractory patients with chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"132","year":"2018","journal-title":"Blood"},{"issue":"S2","key":"bib36-20230924","first-page":"Abstract 2073","article-title":"The impact of age on survival in CLL patients receiving ibrutinib as initial therapy","volume":"37","year":"2019","journal-title":"International Workshop on CLL"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000410","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T05:15:30Z","timestamp":1695532530000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000410"}},"subtitle":["Is 2 (or 3) Better Than 1?"],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000410","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]}}}